Mizuho Forecasts Strong Price Appreciation for Omega Healthcare Investors (NYSE:OHI) Stock

Key Points

• Mizuho has raised its price target for Omega Healthcare Investors (NYSE:OHI) from $37.00 to $40.00, while maintaining a "neutral" rating, suggesting a potential downside of 6.60% from the current stock price.
• Other analysts have also increased their price targets, with Truist Financial setting theirs at $44.00, indicating a consensus price target of $43.75 across multiple analysts for the stock.
• Omega Healthcare Investors reported strong earnings, beating analysts' expectations by posting $0.77 EPS for the last quarter, a significant increase from the previous year, alongside revenue growth of 11.8% year-over-year.

Omega Healthcare Investors (NYSE:OHI - Get Free Report) had its price target raised by analysts at Mizuho from $37.00 to $40.00 in a report issued on Thursday,Benzinga reports. The firm presently has a "neutral" rating on the real estate investment trust's stock. Mizuho's price objective would indicate a potential downside of 6.60% from the stock's current price.

Several other research analysts also recently weighed in on the stock. Truist Financial upped their price target on shares of Omega Healthcare Investors from $39.00 to $44.00 and gave the stock a "hold" rating in a research report on Wednesday, September 3rd. Wells Fargo & Company lifted their target price on Omega Healthcare Investors from $41.00 to $44.00 and gave the company an "overweight" rating in a research report on Wednesday, August 27th. Scotiabank lifted their target price on Omega Healthcare Investors from $39.00 to $42.00 and gave the company a "sector perform" rating in a research report on Thursday, August 28th. Royal Bank Of Canada raised their price target on shares of Omega Healthcare Investors from $39.00 to $41.00 and gave the company a "sector perform" rating in a research report on Thursday, August 7th. Finally, Raymond James Financial reissued an "outperform" rating on shares of Omega Healthcare Investors in a research report on Tuesday, September 2nd. Five research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $43.75.

Omega Healthcare Investors Trading Down 0.0%

NYSE OHI opened at $42.83 on Thursday. The company has a market capitalization of $12.63 billion, a PE ratio of 26.44, a P/E/G ratio of 2.24 and a beta of 0.71. The company has a fifty day moving average of $40.02 and a 200 day moving average of $38.15. Omega Healthcare Investors has a 1 year low of $35.04 and a 1 year high of $44.42. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.10 and a quick ratio of 7.10.

Omega Healthcare Investors (NYSE:OHI - Get Free Report) last posted its earnings results on Thursday, July 31st. The real estate investment trust reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.32. The company had revenue of $235.60 million during the quarter, compared to the consensus estimate of $248.49 million. Omega Healthcare Investors had a net margin of 42.23% and a return on equity of 9.78%. The firm's quarterly revenue was up 11.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.71 earnings per share. Omega Healthcare Investors has set its FY 2025 guidance at 3.040-3.070 EPS. Research analysts forecast that Omega Healthcare Investors will post 2.86 earnings per share for the current year.

Insider Activity at Omega Healthcare Investors

In other news, Director Lisa Egbuonu-Davis sold 2,500 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $40.16, for a total value of $100,400.00. Following the completion of the sale, the director directly owned 18,654 shares of the company's stock, valued at approximately $749,144.64. This represents a 11.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. PFG Investments LLC increased its stake in shares of Omega Healthcare Investors by 20.4% during the first quarter. PFG Investments LLC now owns 70,762 shares of the real estate investment trust's stock worth $2,695,000 after acquiring an additional 11,970 shares during the period. Columbus Macro LLC acquired a new position in Omega Healthcare Investors during the first quarter worth about $6,353,000. GAMMA Investing LLC grew its position in Omega Healthcare Investors by 4,248.2% during the first quarter. GAMMA Investing LLC now owns 174,102 shares of the real estate investment trust's stock worth $6,630,000 after buying an additional 170,098 shares during the period. Two Sigma Advisers LP grew its position in shares of Omega Healthcare Investors by 2,777.6% in the fourth quarter. Two Sigma Advisers LP now owns 333,800 shares of the real estate investment trust's stock valued at $12,634,000 after purchasing an additional 322,200 shares during the last quarter. Finally, Asset Management One Co. Ltd. grew its position in shares of Omega Healthcare Investors by 5.0% in the first quarter. Asset Management One Co. Ltd. now owns 514,967 shares of the real estate investment trust's stock valued at $19,610,000 after purchasing an additional 24,640 shares during the last quarter. 65.25% of the stock is currently owned by institutional investors and hedge funds.

About Omega Healthcare Investors

Omega Healthcare Investors, Inc engages in the provision of financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities, assisted living facilities, independent living facilities, rehabilitation and acute care facilities, and medical office buildings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.